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Abstract
Background: Classification of the antiphospholipid syndrome (APS) relies predomi-
nantly on detecting antiphospholipid antibodies (aPLs). Antibodies against a domain 
I (DI) epitope of anti-β2glycoprotein I (β2GPI) proved to be pathogenic, but are not 
included in the current classification criteria.
Objectives: Investigate the clinical value of detecting anti-DI IgG in APS.
Patients/Methods: From eight European centers 1005 patients were enrolled. Anti-
cardiolipin (CL) and anti-β2GPI were detected by four commercially available solid 
phase assays; anti-DI IgG by the QUANTA Flash® β2GPI domain I assay.
Results: Odds ratios (ORs) of anti-DI IgG for thrombosis and pregnancy morbidity 
proved to be higher than those of the conventional assays. Upon restriction to pa-
tients positive for anti-β2GPI IgG, anti-DI IgG positivity still resulted in significant 
ORs. When anti-DI IgG was added to the criteria aPLs or used as a substitute for anti-
β2GPI IgG/anti-CL IgG, ORs for clinical symptoms hardly improved. Upon removing 
anti-DI positive patients, lupus anticoagulant remained significantly correlated with 
clinical complications. Anti-DI IgG are mainly present in high-risk triple positive pa-
tients, showing higher levels. Combined anti-DI and triple positivity confers a higher 
risk for clinical symptoms compared to only triple positivity.
Conclusions: Detection of anti-DI IgG resulted in higher ORs for clinical manifesta-
tions than the current APS classification criteria. Regardless of the platform used 
to detect anti-β2GPI/anti-CL, addition of anti-DI IgG measured by QUANTA Flash® 
did not improve the clinical associations, possibly due to reduced exposure of the 
pathogenic epitope of DI. Our results demonstrate that anti-DI IgG potentially helps 
in identifying high-risk patients.
K E Y W O R D S
antiphospholipid syndrome, β2-glycoprotein I, domain I, multicenter, pregnancy morbidity, 
thrombosis
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1  | INTRODUC TION
Antiphospholipid syndrome (APS) is a systemic autoimmune dis-
ease characterized by recurrent thrombosis and/or pregnancy 
morbidity in combination with the persistent presence of an-
tiphospholipid antibodies (aPLs).1 Due to the high prevalence of 
thrombosis and pregnancy morbidity in the general population, 
classification of APS mainly relies on laboratory results.2 Five 
different assays that detect aPLs are included in the current re-
vised laboratory criteria: lupus anticoagulant (LAC), detecting a 
phospholipid-dependent prolongation of in vitro clotting times 
and two immunological quantitative assays measuring immuno-
globulin (Ig) G and/or IgM anti-cardiolipin antibodies (anti-CL) 
and anti-β2glycoprotein I (anti-β2GPI) antibodies. Positive tests 
should be repeated with an interval of at least 12 weeks, to avoid 
transient positivity due to infections.3
Although laboratory testing of aPLs is critical to the classifi-
cation of APS, the application and interpretation of these tests 
remain challenging.4,5 The variable clinical performance in conven-
tional commercial and home-made aPL assays not only results from 
the lack of standardization,6,7 but also from the heterogeneity in 
aPLs.8
Accumulating evidence revealed that aPLs are directed against 
phospholipid-bound plasma proteins, of which β2GPI proved to be 
the main target.9-11 β2GPI consists of five homologous domains 
(Domain [D]I-DV). In the native circular or S-shaped conformation, 
the critical DI epitope is not exposed. Upon binding to an anionic 
phospholipid (PL) surface through the positively charged patch on 
DV, β2GPI undergoes a conformational change.12 Consequently, 
the DI-IV spreads out resulting in a more open J shape, exposing 
a cryptic epitope G40-R43 on DI and allowing a subset of anti-DI 
β2GPI autoantibodies to bind.13-15 Various subsets of anti-β2GPI 
antibodies targeting different domains of the protein have been 
described with clear differences in clinical potential. The subpopu-
lation of aPLs that recognize this epitope comprising at least G40-
R43 on DI proved to be pathogenic in vitro/in vivo, and in clinical 
studies,16-20 while aPLs that recognize other domains of β2GPI 
seem to be benign.21-24
The aim of this study is to assess the clinical relevance of 
antibodies against DI of β2GPI in APS patients in an interna-
tional multicenter study and evaluate the added value of de-
tecting anti-DI IgG compared to the conventional assays, as 
well as whether the added value of the anti-DI IgG assay mea-
sured by this QUANTA Flash® depends on the platform used 
to detect anti-β2GPI and anti-CL IgG. The commercially avail-
able chemiluminescence (CIA) assay for anti-DI IgG was used 
in combination with anti-CL and anti-β2GPI assays of differ-
ent manufacturers. Assays were selected based on frequently 
used assays in the external quality control program of the 
ECAT (External quality Control of diagnostic Assays and Tests, 
Voorschoten, the Netherlands) and willingness of manufactur-
ers for collaboration.
2  | MATERIAL AND METHODS
2.1 | Study population
Patient and control samples were collected from eight European medi-
cal centers. The study was approved by the local ethics committees. 
General characteristics (eg, age, gender, ethnicity), clinical characteristics 
(eg, thrombotic events with specification of the type, pregnancy mor-
bidity, autoimmune disease), and previous laboratory determinations (eg, 
LAC tests, IgG/IgM anti-CL, and anti-β2GPI reactivity) were recorded. In 
total, the database enrolled 1005 samples and samples were allocated to 
six different groups according to the information of the centers.
The classification of APS was based on the Sydney criteria.3 
Classification was determined using the local aPL assay panel for 
LAC and IgG/IgM anti-CL or anti-β2GPI antibodies. Control pop-
ulations consisted of patients with an autoimmune disease other 
than APS (eg, systemic lupus erythematosus and systemic sclero-
sis), meeting the criteria for the classification of autoimmune dis-
ease without Sydney criteria thrombotic or pregnancy morbidity 
complications (autoimmune disease other than APS [AID] controls); 
patients that were referred for aPLs testing for other reasons than 
the clinical criteria of APS (eg, subfertility and prolonged activated 
partial thromboplastin time [aPTT], normal controls); patients with 
a previous thrombotic event negatively tested for aPLs (non-APS 
thrombosis); and patients that experienced obstetric complications 
in the absence of aPLs (non-APS obstetric). In the normal con-
trol-female population (n = 169) there was no history of pregnancy 
morbidity. Of the 169 women 119 (70.4%) were characterized by 
subfertility without previous pregnancy; of the 50 other control 
females information on whether they were (successfully) pregnant 
before was not available.
2.2 | Methodology
Anti-CL IgG, anti-CL IgM, anti-β2GPI IgG, and anti-β2GPI IgM were 
detected by four solid phase assays: BioPlex®2200 (Bio-Rad, Bio-Rad 
Essentials
• Antibodies against epitope G40-R43 on domain I (DI) of 
β2GPI proved to be pathogenic in antiphospholipid syn-
drome (APS).
• Detection of anti-DI by chemiluminescence (CIA) on 
top of the APS criteria hardly improves the clinical 
associations.
• Detection of anti-DI in this study confirmed high-risk 
patients.
• The absence of an added value may result from reduced 
exposure of epitope G40-R43 in CIA.
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Laboratories), Phadia® (Thermo Fisher Scientific/Phadia), HemosIL 
AcuStar® (Instrumentation Laboratories), and QUANTA Lite® ELISA 
(Inova Diagnostics). Anti-DI IgG was detected by the CIA of QUANTA 
Flash® β2GPI domain I assay (Inova Diagnostics) on the ACL AcuStar® 
platform. All tests were performed between February 2016 and 
October 2016 by a single technician in the Ghent University Hospital 
following the instructions of the manufacturer. Values below the cal-
culated limit of detection (LOD) were replaced by the LOD. The cut-
off values from the manufacturers’ recommendation were confirmed 
in 20 healthy individuals according to the Clinical and Laboratory 
Standards Institute (CLSI) guidelines25 and guidance from the 
Scientific and Standardization Committee (SSC) of the International 
Society on Thrombosis (ISTH).5 Based on the cut-off values (20 arbi-
trary units ie U/mL, GPL, MPL, SGU, SMU on platforms of HemosIL 
AcuStar®, BioPlex®2200, and QUANTA Lite® ELISA; 10 arbitrary 
units on Phadia® for anti-CL IgG/IgM and anti-β2GPI IgG/IgM; 20 
chemiluminescence units [CU] on QUANTA Flash® for anti-DI IgG), 
positive samples were identified. LAC positivity was determined by 
the individual center, according to the ISTH guidelines.7
2.3 | Statistics
Statistical analyses were performed using IBM SPSS® Statistics 24 
(IBM SPSS). To avoid a possible bias induced by the classification 
performed by the eight individual centers, we selected “clinically 
affected versus clinically not affected” as outcome variable instead 
of “APS versus non-APS classification.” Relationships between the 
different laboratory assays and the clinical events (thrombosis or 
pregnancy morbidity) of the patients were investigated by calcu-
lating odds ratios (ORs) and 95% confidence intervals (95% CI) in 
the respective subpopulations. To determine the association with 
thrombosis and pregnancy morbidity, analysis was restricted to the 
thrombosis subpopulation (thrombotic APS, non-APS thrombosis, 
AID, and normal controls [n = 851]) and the pregnancy morbidity 
subpopulation (obstetric APS, non-APS obstetric, female AID, and 
female normal controls [n = 481]), respectively. Subsequently, the 
chi-squared test was used for the comparison of dichotomous vari-
ables, and anti-DI IgG titers were compared between groups by the 
Kruskal-Wallis H test (more than two groups) or Mann-Whitney U 
test (two groups). Finally, the kappa agreement of anti-DI IgG and 
conventional aPL tests was studied via the chi-squared test, and 
the correlation between the titer of anti-DI IgG, anti-β2GPI IgG, 
and anti-CL IgG was performed by a Spearman rank correlation 
test. P < .05 (two-tailed) were considered statistically significant.
3  | RESULTS
3.1 | Characteristics of the study population
The patients’ demographic data and clinical characteristics are sum-
marized in Table 1. To evaluate associations with thrombotic events 
and pregnancy morbidity separately, the characteristics of two sub-
populations are shown in Table 1.
3.2 | Association between anti-DI IgG and clinical 
symptoms of APS
Independent of the platform, a significant association with clinical 
events was found for all tested aPL assays, with ORs varying from 
2.7 (95% CI 1.9-3.9) to 5.4 (95% CI 3.0-9.6) for thrombosis, 2.3 (95% 
CI 1.5-3.3) to 4.1 (95% CI 2.5-6.6) for arterial thrombosis, 2.0 (95% 
CI 1.4-2.8) to 2.8 (95% CI 1.9-4.2) for venous thrombosis, and 2.7 
(95% CI 1.7-4.3) to 5.6 (95% CI 3.1-9.9) for pregnancy morbidity 
(Table 2A). Compared to the criteria aPL assays, detection of anti-DI 
IgG was less sensitive (21.9%/26.6% for thrombosis/pregnancy mor-
bidity), but more specific (94.9%/93.9% for thrombosis/pregnancy 
morbidity), overall resulting in higher ORs for both clinical criteria 
of APS compared to LAC, anti-β2GPI, or anti-CL IgG except for the 
QUANTA Lite® ELISA platform. Similar ORs of anti-DI were found 
for thrombosis and pregnancy morbidity, and no difference in as-
sociation was observed between venous versus arterial thrombosis. 
Interestingly, upon restriction to patients positive for anti-β2GPI 
IgG, anti-DI IgG positivity still resulted in significant—albeit lower—
ORs for both clinical criteria of APS except for the QUANTA Lite® 
ELISA platform (Table 2B).
3.3 | Additional clinical value of detecting anti-DI 
IgG on top of the currently used laboratory tests
Table 3 shows the number of patients testing positive or negative 
for anti-DI IgG in relation to positivity for LAC or anti-β2GPI IgG or 
at least one of the criteria aPL panel measured by HemosIL AcuStar® 
considering the previously defined subpopulations. The results of 
the other three solid phase assays can be found in Table S1 in sup-
porting information.
From Table 3, looking at the thrombosis subpopulation, 13 out 
of the 19 LAC negative anti-DI positive patients had thrombosis. 
Additionally, the four samples testing negative for anti-β2GPI IgG 
by HemosIL AcuStar® but positive for anti-DI IgG all had thrombo-
sis. Similarly, the two individuals testing negative for the criteria 
aPL panel by HemosIL AcuStar® and positive for anti-DI IgG both 
suffered from thrombosis. Concerning the pregnancy morbidity 
subpopulation, 12 out of the 18 LAC negative anti-DI IgG positive 
patients experienced pregnancy morbidity. One patient testing 
negative for anti-β2GPI IgG by HemosIL AcuStar® and positive 
for anti-DI IgG had pregnancy morbidity. Moreover, only one in-
dividual negative for the criteria aPL panel by HemosIL AcuStar® 
tested positive for anti-DI IgG and suffered from pregnancy mor-
bidity. Looking at Table S1, both for the thrombosis subpopula-
tion or the pregnancy morbidity subpopulation, similar results 
were found when anti-β2GPI or anti-CL IgG/IgM were detected 
by BioPlex®2200 although more samples tested negative for 
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anti-β2GPI IgG by Phadia® and QUANTA Lite® ELISA but positive 
for anti-DI IgG, and most of them had thrombosis or pregnancy 
morbidity. Including LAC, fewer individuals negative for the cri-
teria aPL panel tested positive for anti-DI IgG and suffered from 
clinical events.
To assess the additional clinical value of anti-DI IgG on top of the 
currently used aPL measured by different platforms, anti-DI IgG was 
added to the criteria aPL panel or used as a substitute for anti-β2GPI 
IgG and anti-CL IgG in the criteria aPL panel. For all platforms, the 
addition of anti-DI IgG to the current criteria aPL panel hardly re-
sulted in an increase of the OR for thrombosis or pregnancy morbid-
ity. Replacement of anti-β2GPI IgG and anti-CL IgG by anti-DI IgG 
resulted in comparable ORs for both clinical symptoms. For all plat-
forms, a small increase was observed in specificity when replacing 
anti-β2GPI IgG and anti-CL IgG by anti-DI IgG, mostly accompanied 
by a decrease in sensitivity (Table 4).
TA B L E  1   Demographic and clinical characteristics of the study population
The thrombosis subpopulation 
(N = 851) Thrombotic APS AID Non-APS thrombosis Normal controls
Patients (N) 258 196 204 193
Gender
Female (N[%]) 165 (64.0) 158 (80.6) 116 (56.9) 169 (87.6)
Age (Mean ± SD, y) 49.6 ± 14.7 46.4 ± 14.2 46.5 ± 14.1 39.4 ± 11.0
Clinical features (N [%])
Thrombosis 258 (100.0) 0 204 (100) 0
AT 54 (20.9) 0 47 (23.0) 0
VT 160 (62.0) 0 149 (73.0) 0
AT + VT 26 (10.1) 0 5 (2.5) 0
Small vessel 4 (1.6) 0 0 (0) 0
Pregnancy morbidity 23 (8.9) 2 (1.0) 0 0
A 6 (2.3) 0 0 0
B 6 (2.3) 0 0 0
C 6 (2.3) 0 0 0
NS/ non-Sydney criteria 5 (1.9) 2 (1.0) 0 0
The pregnancy morbidity 
subpopulation (N = 481) Obstetric APS AID-female Non-APS obstetric Normal controls-female
Patients (N) 121 158 33 169
Age (Mean ± SD, y) 34.3 ± 6.6 45.4 ± 14.5 32.7 ± 5.6 38.4 ± 9.6
Clinical features (N [%])
Thrombosis 9 (7.4) 0 0 0
AT 3 (2.5) 0 0 0
VT 5 (4.1) 0 0 0
AT + VT 1 (0.8) 0 0 0
Small vessel 0 (0) 0 0 0
Pregnancy morbidity 121 (100.0) 2 (1.3) 33 (100.0) 0
A 35 (28.9) 0 9 (27.3) 0
B 10 (8.3) 0 4 (12.1) 0
C 67 (55.4) 0 6 (18.2) 0
B + C 2 (1.7) 0 1 (3.0) 0
A + C 3 (2.5) 0 1 (3.0) 0
NS/non-Sydney 
criteria
4 (3.3) 2 (1.3) 12 (36.4) 0
Note: A, history of three or more consecutive unexplained losses <10 weeks gestation; B, history of fetal death after 10 weeks before gestation; C, 
history of premature birth(s) before 34 weeks due to preeclampsia or placental insufficiency based on the Sydney classification criteria. NS, non-
specified pregnancy complications; non-Sydney criteria, not fulfilling Sydney criteria for pregnancy morbidity.
Abbreviations: AID, autoimmune disease other than APS; APS, antiphospholipid syndrome; AT, arterial thrombosis; N, number of patients; SD, 
standard deviation; VT, venous thrombosis.
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To investigate if anti-DI antibodies are the only pathogenic anti-
bodies, we re-evaluated the correlation of LAC, anti-CL IgG, and an-
ti-β2GPI IgG with clinical manifestations of APS in anti-DI IgG negative 
patients. Interestingly, upon removal of anti-DI positive samples, posi-
tivity for LAC still resulted in significant ORs for thrombosis (2.5, 95% 
CI 1.7-3.5) and for pregnancy morbidity (3.9, 95% CI 2.4-6.4) while 
correlations for anti-β2GPI IgG and anti-CL IgG antibodies were no 
longer statistically significant except for when the anti-CL IgG was 
measured by Phadia® and QUANTA Lite® ELISA (OR for thrombosis 
of 2.3 (95% CI 1.1-4.8) and 2.4 (95% CI 1.0-5.5), respectively; Table 5).
3.4 | Distribution of anti-DI IgG titers according 
to the patient's antibody profile
For both the thrombosis and pregnancy morbidity subpopulation, 
all individuals were grouped according to their aPL profile into triple 
positive (LAC +, anti-CL IgG/IgM +, anti-β2GPI IgG/IgM +), double 
positive (LAC −, anti-CL IgG/IgM +, anti-β2GPI IgG/IgM + or LAC 
+, anti-CL IgG/IgM +, anti-β2GPI IgG/IgM − or LAC +, anti-CL IgG/
IgM −, anti-β2GPI IgG/IgM +), and single positive (isolated positive 
for LAC, anti-CL IgG/IgM, or anti-β2GPI IgG/IgM). Results were com-
pared with those of patients without any aPL reactivity (negative 
control). The different antibody profiles with their characteristics are 
shown in Table 6 for anti-β2GPI and anti-CL measured by HemosIL 
AcuStar® and in Table S2-S4 in supporting information for anti-β2GPI 
and anti-CL measured by the three other solid-phase assays.
Furthermore, we compared anti-DI IgG titers in the triple positive, sol-
id-phase double-positive (anti-CL IgG/IgM positive and anti-β2GPI IgG/
IgM positive but LAC negative), combined single-positive group (isolated 
LAC +, and isolated anti-CL IgG/IgM +, and isolated anti-β2GPI IgG/IgM 
+), and the negative control. Comparison of anti-DI IgG titers between 
four aPL profile groups for anti-β2GPI and anti-CL measured by four 
assays is shown in Figure 1. Looking at HemosIL AcuStar®, in both the 
thrombosis subpopulation and pregnancy morbidity subpopulation an-
ti-DI titers were significantly higher in triple positive samples compared to 
the other aPL profile groups, followed by the solid-phase double-positive 
samples. No difference was observed between anti-DI titers of combined 
single positive and negative samples. Similar results were found for the 
three other assays, except that there was a significant difference between 
anti-DI titers of combined single positive and negative samples for an-
ti-β2GPI and anti-CL measured by QUANTA Lite® ELISA (Figure 1).
TA B L E  3   Number of patients testing positive (+) or negative (−) for anti-DI IgG in relation to positivity for LAC or anti-β2GPI IgG or at 
least one of the criteria aPL panel measured by HemosIL AcuStar®, see Table S1 for the other platforms
  
Thrombosis 
subpopulation 
(N = 851) With T (N = 462)
Without T 
(N = 389)
Pregnancy 
morbidity 
subpopulation 
(N = 481) With P (N = 154)
Without P 
(N = 327)
  LAC LAC LAC LAC LAC LAC
  + − + − + − + − + − + −
Anti-DI IgG + 102 19 88 13 14 6 43 18 29 12 14 6
− 172 558 114 247 58 311 92 328 46 67 46 261
Total  274 577 202 260 72 317 135 346 75 79 60 267
  Anti-CL IgG Anti-CL IgG Anti-CL IgG Anti-CL IgG Anti-CL IgG Anti-CL IgG
  + − + − + − + − + − + −
Anti-DI IgG + 114 7 95 6 19 1 59 2 40 1 19 1
− 29 701 19 342 10 359 14 406 5 108 9 298
Total  143 708 114 348 29 360 73 408 45 109 28 299
  Anti-β2GPI IgG Anti-β2GPI IgG Anti-β2GPI IgG Anti-β2GPI IgG Anti-β2GPI IgG Anti-β2GPI IgG
  + − + − + − + − + − + −
Anti-DI IgG + 117 4 97 4 20 0 60 1 40 1 20 0
− 75 655 42 319 33 336 41 379 11 102 30 277
Total  192 659 139 323 53 336 101 380 51 103 50 277
  Criteria aPL 
panela
Criteria aPL 
panela
Criteria aPL 
panela
Criteria aPL panela Criteria aPL 
panela
Criteria aPL 
panela
  + − + − + − + − + − + −
Anti-DI IgG + 119 2 99 2 20 0 60 1 40 1 20 0
− 230 500 142 219 88 281 134 286 63 50 71 236
Total  349 502 241 221 108 281 194 287 103 51 91 236
Abbreviations: aPL, antiphospholipid antibody; β2GPI, β2glycoprotein I; DI, domain I; IgG (M), immunoglobulin G (M); LAC, lupus anticoagulant; N, 
number of patients; P, pregnancy morbidity; T, thrombosis.
aCriteria aPL panel positivity: patients testing positive for at least one of the criteria aPL panel (ie LAC, anti-CL IgG/M and/or anti-β2GPI IgG/M). 
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3.5 | Association of triple positivity with anti-
DI positivity
The association between DI positivity and triple positivity was studied in 
detail for anti-β2GPI and anti-CL measured by the Acustar® (Table 6). As 
to the thrombosis subpopulation (Table 6), positive values of anti-DI IgG 
were found in 100 out of 134 individuals with triple positivity (74.6%), 
compared with 44.1% (15/34) in the solid-phase double-positive group 
(Pearson chi-square, P = .002). Combined single-positive (2/146 = 1.4%) 
and aPL-negative patients (2/502 = 0.4%) hardly showed any anti-DI IgG 
reactivity (Fisher's exact test, P < .0001). A good agreement was found 
between triple positivity and anti-DI IgG positivity (Kappa value = 0.746, 
P < .0001). In this triple positive group, 87.0% (87/100) of anti-DI IgG-
positive individuals had a history of thrombosis, compared with 70.6% 
(24/34) of anti-DI IgG negative patients (Pearson chi-square, P = .028).
Concerning the pregnancy morbidity subpopulation (Table 6), 
positive values of anti-DI IgG were found in 42 out of 56 individuals 
with triple positivity (75.0%), compared with 48.6% (17/35) in the sol-
id-phase double-positive group (Pearson chi-square, P = .013). As seen 
in the thrombosis subpopulation, the combined single-positive group 
(0/81 = 0%) and aPL negative patients (1/287 = 0.3%) hardly showed 
anti-DI IgG reactivity (Fisher's exact test, P < 0.0001). Albeit lower 
than for the thrombosis subpopulation, also in the pregnancy morbid-
ity subpopulation a good agreement was demonstrated between tri-
ple positivity and anti-DI IgG (Kappa value = 0.679, P < .0001). In this 
triple-positive group, 69.0% (29/42) of anti-DI IgG positive individuals 
had a history of pregnancy morbidity, compared with 35.7% (5/14) of 
anti-DI IgG negative patients (Fisher's exact test, P = .027). In general, 
similar conclusions can be drawn when anti-β2GPI and anti-CL were 
measured by the other assays (Tables S2-S5 in supporting information).
Interestingly, both for thrombosis and pregnancy morbidity, the 
ORs of anti-DI IgG were higher than the ORs of triple positivity except 
when anti-CL and anti-β2GPI were measured by the QUANTA Lite® 
ELISA platform for thrombosis. To verify if anti-DI positivity has an 
added value in risk stratification compared to triple positivity, ORs of 
combined triple positivity and DI positivity were calculated for throm-
bosis and pregnancy morbidity. As to thrombosis, combined positiv-
ity resulted in higher OR compared to the separate OR for both triple 
positivity and DI reactivity. For pregnancy morbidity, ORs of anti-DI 
plus triple positivity were higher compared to ORs of triple positivity, 
but hardly improved compared to OR of anti-DI positivity (Table 2A).
Furthermore, as to the thrombosis subpopulation, within the 
triple-positive group for anti-β2GPI and anti-CL measured by 
Acustar®, anti-DI IgG titers varied greatly but no significant differ-
ence was observed between patients with thrombosis (n = 111) and 
unaffected individuals (n = 23), with a median (quartile[Q]25-Q75) 
anti-DI IgG titer of, respectively, 169.0 CU (25.7-761.3) and 63.7 
CU (3.7-625.7) (Mann-Whiney U test, P = .084). Similarly, concern-
ing the pregnancy morbidity subpopulation, anti-DI IgG titers dif-
fered greatly but no significant difference between patients with 
pregnancy morbidity (n = 34) and unaffected individuals (n = 22) 
could be demonstrated with a median (Q25-Q75) anti-DI IgG titer 
of 200.2 CU (49.6-462.1) and 65.0 CU (3.7-654.3), respectively 
(Mann-Whiney U test, P = .179). Similar results were obtained with 
the three other assays, although for the BioPlex®2200 (thrombosis 
and pregnancy morbidity) and Phadia® (thrombosis) results reached 
statistical significance (Table S6 in supporting information).
TA B L E  5   ORs of LAC, anti-CL IgG and anti-β2GPI IgG with clinical manifestations of APS upon the removal of anti-DI IgG positive 
patients
Thrombosisa Pregnancy morbidityb
Population (N#) Positive (N$) OR 95% CI Population (N#) Positive (N$) OR 95% CI
LAC 730 172 2.5 1.7-3.5 420 92 3.9 2.4-6.4
Anti-CL IgG
HemosIL AcuStar® 730 29 2.0 0.9-4.4 420 14 1.5 0.5-4.7
BioPlex® 2200 730 47 1.3 0.7-2.3 420 29 1.2 0.5-2.8
Phadia® 730 35 2.3 1.1-4.8 420 16 2.2 0.8-6.0
QUANTA Lite 
ELISA®
730 26 2.4 1.0-5.5 420 11 2.3 0.7-7.8
Anti-β2GPI IgG
HemosIL AcuStar® 730 75 1.3 0.8-2.2 420 41 1.0 0.5-2.1
BioPlex® 2200 730 49 1.1 0.6-1.9 420 30 1.2 0.5-2.7
Phadia® 730 30 1.6 0.7-3.3 420 16 1.2 0.4-3.7
QUANTA Lite 
ELISA®
730 10 4.2 0.9-19.7 420 2 2.7 0.2-44.1
Note: Significant ORs are shown in bold and calculated according to the outcome variable “clinically affected versus clinically not-affected patients.”
Abbreviations: APS, antiphospholipid syndrome; β2GPI, β2glycoprotein I; CL, cardiolipin; DI, domain I; IgG, immunoglobulin G; LAC, lupus 
anticoagulant; N#, number of patients; N$, number of biomarker positive cases; OR, odds ratio; 95% CI, 95% confidence interval.
aThrombotic APS + non-APS thrombosis versus non-thrombotic population (AID + normal controls). 
bObstetric APS + non-APS obstetric versus non-obstetric population (AID - female + normal controls - female). 
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3.6 | Correlation between detection of anti-DI 
IgG and anti-β2GPI IgG and anti-CL IgG
Concordance was evaluated by comparing the results of the detection 
of IgG anti-DI antibodies with anti-β2GPI IgG and anti-CL IgG measured 
by four solid-phase assays (Table 7). A good agreement was established 
between IgG anti-DI antibodies and IgG anti-CL as well as with IgG 
anti-β2GPI antibodies (Kappa value = 0.656-0.861) in the thrombosis 
subpopulation (Table 7A) and the pregnancy morbidity subpopulation 
(Table 7B). The IgG anti-DI antibody titers were likewise significantly 
correlated with IgG anti-CL titers and IgG anti-β2GPI titers (Spearman's 
rho = 0.563-0.842) in the thrombosis subpopulation (Table 7A) and the 
pregnancy morbidity subpopulation (Table 7B; all P < .0001).
4  | DISCUSSION
Solid phase aPL assays included in the laboratory criteria suffer from 
a lack of standardization, limiting their utility in clinical practice. 
F I G U R E  1   Distribution of the titer of anti-DI IgG according to distinct antibody profiles for anti-CL and anti-β2GPI measured by HemosIL 
AcuStar®, BioPlex®2200, Phadia®, and QUANTA Lite® ELISA in the thrombosis subpopulation (A) and pregnancy morbidity subpopulation 
(B). Investigated aPL profiles include triple positive (LAC +, anti-CL IgG/IgM +, anti-β2GPI IgG/IgM +), solid phase double positive (LAC −, 
anti-CL IgG/IgM +, anti-β2GPI IgG/IgM +), and combined single positive (isolated LAC +, and isolated anti-CL IgG/IgM +, and isolated anti-
β2GPI IgG/IgM +). Patients without any aPL reactivity were defined as negative controls. Titer of anti-DI IgG are expressed as the median 
with interquartile ranges within each profile; dashed lines indicate the cut-off value of anti-DI IgG (20 CU). *P < .05, **P < .01, ***P < .0001, 
ns: not significant. Abbreviations: aPL, antiphospholipid antibody; DI, domain I; IgG, immunoglobulin G; CU, chemiluminescence units
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Variability results not only from methodological shortcomings but 
also from the heterogeneity of aPLs.5,7 More and more literature evi-
dence suggests that detection of a subset of aPLs reactive against 
DI of β2GPI is a promising classification or risk stratification tool in 
APS.26,27 However, a recent review concluded inconsistent results 
about the added value of the detection of anti-DI IgG compared to 
conventional aPL tests, most probably due to differences in study 
design, study population, and the methodology to detect the anti-DI 
antibodies.28
In this multicenter study, all samples were measured for aPL re-
activity by one technician in the same lab to avoid variability coming 
from differences in working conditions. In most studies evaluating 
the added value of anti-DI IgG, the only commercially available assay 
(CIA of QUANTA Flash®) is compared with anti-β2GPI and anti-CL of 
the same manufacturer.29-35 Importantly, we hypothesized that the 
added value of the anti-DI IgG assay measured by QUANTA Flash® 
depends on the platform used to detect anti-β2GPI and anti-CL IgG. 
This hypothesis comes from our previously published results demon-
strating a variable exposure of the G40-R43 epitope on domain I 
of β2GPI coated in the different commercially available anti-CL and 
anti-β2GPI assays.8,36,37 In this multicenter study, we therefore de-
termined the added value of anti-DI testing to the current APS clas-
sification criteria, when anti-CL and anti-β2GPI were measured by 
four different commercially available assays.
As literature is inconclusive whether the same aPL subset in-
duces thrombosis and pregnancy morbidity, separate analyses were 
performed in a thrombosis and pregnancy morbidity subpopulation, 
including proper control populations. Both for the thrombosis and 
the pregnancy morbidity subpopulation, we found that the detection 
of anti-DI IgG was less sensitive but more specific compared to the 
laboratory criteria aPL tests, resulting in a higher OR for thrombosis 
and pregnancy morbidity compared to LAC, anti-β2GPI, or anti-CL 
IgG, except for the QUANTA Lite® ELISA. Interestingly, upon restric-
tion to patients positive for anti-β2GPI IgG, anti-DI IgG positivity 
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still resulted in significant ORs for clinical complications, except 
for the QUANTA Lite® ELISA (Table 2B); that could be explained by 
the lower number of anti-β2GPI IgG detected by this assay (Table 
S1). These findings are consistent with previous studies.19,20,29,30,32 
Based on these results, apart from those obtained by the QUANTA 
Lite® ELISA, we expected anti-DI IgG to have an additional value on 
top of the current laboratory criteria, or to be a candidate to replace 
the anti-β2GPI IgG detection. Contrary to our expectation, the ad-
dition of anti-DI or replacement of anti-β2GPI IgG by anti-DI hardly 
improved the ORs for thrombosis or pregnancy morbidity. The ab-
sence of an added value of anti-DI to the current aPL criteria panel 
was also found in previous studies.34,35
This at-first-sight contradiction can be explained by the results 
presented in Table 3 and Table S1. Independent of the assay used, only 
a few individuals (n = 11) negative for the criteria aPL panel (with one 
or more platforms) become positive when anti-DI IgG is added to the 
criteria aPLs panel or used as a substitute for anti-β2GPI IgG and/or 
anti-CL IgG, even though most of them experienced clinical events 
(n = 7 with thrombosis, n = 2 with pregnancy morbidity). Of note, de-
spite anti-DI IgG positivity, the titers of anti-DI IgG in these individuals 
proved to be low (from 21.1 to 73.2 CU).
Interestingly, upon removal of anti-DI IgG positive patients, an-
ti-CL IgG and anti-β2GPI IgG were no longer significantly correlated 
with thrombosis and pregnancy morbidity, except for anti-CL IgG mea-
sured by Phadia® and by QUANTA Lite® ELISA (OR for thrombosis of 
2.3 [95% CI 1.1-4.8] and 2.4 [95% CI 1.0-5.5], respectively; Table 5). 
Although the OR for thrombosis of anti-CL IgG measured by Phadia® 
and by QUANTA Lite® ELISA was still significant, the lower limit was 
adjacent to 1. These findings are in agreement with previous studies 
demonstrating that especially anti-DI antibodies are pathogenic while 
antibodies targeting other domains such as domain 4/5 are innocent 
or even protective antibodies.20,23,38,39
We previously demonstrated that the large variability observed 
in commercially available anti-β2GPI assays results at least in part 
from a variable exposure of the pathogenic G40-R43 DI epitope.8 
Importantly, our recent data show that, as for anti-β2GPI IgG assays, 
the pathogenic DI epitope is not exposed correctly in the commercially 
available anti-DI CIA assay.28 Furthermore, both as categorical vari-
ables (positive/negative) and as quantitative variables (titer), anti-DI 
IgG strongly correlated with anti-CL IgG and anti-β2GPI IgG on the 
same AcuStar® CIA. The high correlation between anti-DI IgG and an-
ti-β2GPI IgG suggests a high overlap between both assays performed 
on the automated CIA platform. Previous studies also observed a high 
agreement (69%-92%) between anti-DI IgG and anti-β2GPI IgG when 
measured using the CIA methodology.29,34,35,40 These results may ex-
plain the absence of an added value of measuring anti-DI using this 
assay. In this study, and also for the other platforms, a high agree-
ment was found between anti-DI and the anti-CL IgG and anti-β2GPI 
IgG and no added value of measuring anti-DI could be demonstrated 
(Table 7).
Of note, apart from the anti-DI CIA assay used in this study, other 
methods are available to detect anti-DI antibodies.28 Previously a 
home-made two-step ELISA strongly indicated that testing for IgG T
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anti-DI enables identification of the patients at highest risk for de-
veloping thrombosis or pregnancy morbidity.19,20 In contrast to the 
results obtained by CIA assays, only 50% of the anti-β2GPI IgG an-
tibodies tested by this home-made two-step ELISA were demon-
strated to be reactive against DI. Importantly, using this two-step 
ELISA assay, correct exposure of the G40-R43 epitope was already 
confirmed.20 The added value of measuring anti-DI reactivity using 
this assay remains to be determined.
Interestingly, LAC remained significantly correlated with throm-
bosis and pregnancy morbidity upon removal of anti-DI IgG positive 
patients. Further illustrated by the only fair to moderate agree-
ment between IgG anti-DI and functional LAC in the thrombosis 
subpopulation (Kappa value = 0.398) and the pregnancy morbidity 
subpopulation (Kappa value = 0.320), these data illustrate that the 
CIA anti-DI IgG assay only detects part of the pathogenic aPLs. The 
presence of pathogenic anti-phosphatidylserine/prothrombin (an-
ti-PS/PT) antibodies able to induce LAC positivity may explain the 
remaining correlation between LAC and thrombosis. Indeed, previ-
ous studies have demonstrated correlations of anti-PS/PT with clini-
cal symptoms in APS patients and positivity proved to be associated 
with LAC.41,42
Evidence is growing that the determination of combined anti-
body positivity helps to categorize patients according to their risk 
profile. Especially triple-positive patients (positive for LAC and 
anti-CL and anti-β2GPI IgG/IgM) show a strong association with 
thrombotic and obstetric manifestations.43,44 Clinical studies con-
firm that triple positivity in APS patients and asymptomatic aPL 
carriers indicates a high risk of recurrence of thrombosis or de-
velopment of a first thrombotic event, respectively.44,45 Although 
identification of triple positives is dependent on the solid-phase 
assay used,46 the percentage of anti-DI IgG positives in individu-
als with distinct antibody profiles were comparable for the four 
tested solid-phase assays. In this study, a very good agreement 
was found between triple positivity and anti-DI IgG positivity, ir-
respective of the solid-phase assay used (Table S5), which is con-
sistent with previous studies.30-32,35,40 Moreover, independent of 
the platform used to measure anti-CL and anti-β2GPI IgG/IgM, 
we observed that anti-DI IgG antibodies are mainly present in 
triple positive individuals, also showing significantly higher titers 
compared to patients with other aPL profiles. More importantly, 
within the triple positive group, a higher percentage of clinically 
affected cases was present in the anti-DI IgG positive compared 
to the anti-DI IgG negative group. Furthermore, the higher ORs of 
combined DI and triple positivity for both thrombosis and preg-
nancy morbidity compared to only triple positivity, support the 
idea that detection of anti-DI IgG is interesting to identify pa-
tients at risk.
We acknowledge that our study has some limitations. First, as 
in both the thrombotic and obstetric patient groups, a small num-
ber of patients (8.9% and 7.4%, respectively) also suffers from the 
other clinical manifestation, the correlation with the specific clini-
cal manifestation may be affected by the comorbidity of the other 
manifestation. Also, the different groups in our study population did 
not match according to age and gender, but were representative to 
population groups tested in daily practice. Another limitation of our 
study is the retrospective design. Interestingly, in the AID and nor-
mal control group, a number of the triple positives were also positive 
for anti-DI reactivity (depending on the platform 11/22 [50%]-
9/14 [64%] for AID; 1/3 [33%]-2/4 [50%] for the normal controls). 
Prospective studies are necessary to verify the risk of patients with 
these characteristics to develop clinical manifestations of APS, with 
possible implications for their treatment.
This study showed again that the choice of the commercial as-
says used to detect the presence of antiphospholipid antibodies 
influences the classification of APS. It is impossible to determine 
which commercial assay is the best because we lack a gold standard. 
However, a good agreement with a domain I specific assay seems to 
be essential because antibodies against DI have shown to be patho-
genic in animal models of APS.
5  | CONCLUSION
Despite the higher OR of anti-DI antibody detection for clini-
cal manifestations of APS, our study was unable to demonstrate 
an added value of measuring anti-DI IgG on top of the laboratory 
criteria, independent of the platform used to measure anti-CL and 
anti-β2GPI. We put the hypothesis forward that the reduced expo-
sure of the pathogenic DI epitope in this automated assay possibly 
explains the absence of an added value. Therefore, it may be inter-
esting to re-evaluate the added value of anti-DI using the in-house 
anti-DI assay previously developed, for which correct exposure of 
the pathogenic epitope was already demonstrated. The high corre-
lation between anti-DI IgG and triple positivity indicates that anti-DI 
IgG positivity confirms the patients at higher risk for clinical events 
in APS. Importantly, combined DI and triple positivity confirms a 
higher risk for both thrombosis and pregnancy morbidity compared 
to only triple positivity. As LAC positivity remains significantly cor-
related with thrombosis and pregnancy morbidity upon removal of 
anti-DI positive patients, the anti-DI IgG assay only detects part of 
the pathogenic aPLs.
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